Sixteen patients with advanced hematologic malignancies were transplanted with HLA-identical allogeneic peripheral blood stem cells (PBSCs) that were selected for CD34+ cells by an avidin-biotin immunoadsorption technique. The median age of patients was 48 years (range, 37 to 67). Patients received 12.0 or 13.2 Gy of total body irradiation followed by 120 mg/kg of cyclophosphamide. Normal donors received 16 mg/kg of granulocyte-colony stimulating factor on days 1 t o 6 followed by PBSC harvests on days 4 t o 7. PBSC harvests were processed each day on a single avidin-biotin column containing an antibody t o the CD34 antigen and processed cells were infused without cryopreservation daily for 4 consecutive days. Prophylaxis against graft-versus-host disease (GVHD) consisted of cyclosporine alone for 5 patients and CSA plus methotrexate for l l patients. ECENT STUDIES have evaluated the use of granulo-R cyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (PBSCs) as an alternative to bone marrow (BM) as a source of allogeneic hematopoietic stem ~e1ls.I'~ Preliminary data suggest that allogenic PBSC transplants result in more rapid engraftment without an apparent increase in acute GVHD as compared to BM, but the numbers of patients treated are too few and follow-up too short to make any conclusions conceming effects on chronic graftversus-host disease (GVHD), relapse or survival. However, the large number of T cells in PBSC collections raises the concern that allogeneic grafts using PBSCs may be associated with more GVHD, especially if applied in settings There were no episodes of graft failure or rejection. This study shows that allogeneic transplantation using CD34' selected PBSC results in prompt and sustained engraftment. CD34+ selection, as employed in this preliminary study, however, resulted in an apparently higher rate of acute and chronic GVHD. However, The sample size is quite small and precludes a more definitive conclusion regarding GVHD.
Sixteen patients with advanced hematologic malignancies were transplanted with HLA-identical allogeneic peripheral blood stem cells (PBSCs) that were selected for CD34+ cells by an avidin-biotin immunoadsorption technique. The median age of patients was 48 years (range, 37 to 67). Patients received 12.0 or 13.2 Gy of total body irradiation followed by 120 mg/kg of cyclophosphamide. Normal donors received 16 mg/kg of granulocyte-colony stimulating factor on days 1 t o 6 followed by PBSC harvests on days 4 t o 7. PBSC harvests were processed each day on a single avidin-biotin column containing an antibody t o the CD34 antigen and processed cells were infused without cryopreservation daily for 4 consecutive days. Prophylaxis against graft-versus-host disease (GVHD) consisted of cyclosporine alone for 5 patients and CSA plus methotrexate for l l patients. A median of 18.64 (6.74 t o 34.97) x IO' CD34+ cells/kg patient body weight were collected from each donor. A median of 8.96 (2.62 t o 17.34) x 10' CD34+ cells/kg patient body weight were recovered after avidin-biotin adsorption which represented a median CD34+ cell yield of 5396 (189' 0 t o 77%) with a median purity of 62% (34% t o 8240). There was a reduction in CD3' cells from a median of 557. ECENT STUDIES have evaluated the use of granulo-R cyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (PBSCs) as an alternative to bone marrow (BM) as a source of allogeneic hematopoietic stem ~e1ls.I'~ Preliminary data suggest that allogenic PBSC transplants result in more rapid engraftment without an apparent increase in acute GVHD as compared to BM, but the numbers of patients treated are too few and follow-up too short to make any conclusions conceming effects on chronic graftversus-host disease (GVHD), relapse or survival. However, the large number of T cells in PBSC collections raises the concern that allogeneic grafts using PBSCs may be associated with more GVHD, especially if applied in settings (2.19 t o 3.14) log reduction in T cells. One patient died of infection on day 3 posttransplant and was unevaluable for recovery of neutrophils. The median day t o recovery of 500 neutrophilslmL was 15 (8 t o 26) in the remaining 15 patients. Six of 16 patients failed t o achieve a platelet count of 20,000/ mL before death on days 3 t o 97 of transplant-related complications. The median day t o achieving platelets of 20,000 mL in the remaining 10 patients was 11 (7 t There were no episodes of graft failure or rejection. This study shows that allogeneic transplantation using CD34' selected PBSC results in prompt and sustained engraftment. CD34+ selection, as employed in this preliminary study, however, resulted in an apparently higher rate of acute and chronic GVHD. However, The sample size is quite small and precludes a more definitive conclusion regarding GVHD. where GVHD is of greater risk, such as in older patients or in patients receiving mismatched or unrelated transplants. The ability to mobilize and collect large quantities of PBSCs, as measured by the CD34+ cell content, offers unique opportunities for graft manipulation.
Allogeneic transplants using T-cell depleted BM are associated with a lower incidence of GVHD but an increase in the incidence of graft failure and elapse.''^^ Although the increased incidence of graft failure is usually attributed to the low number of T cells infused, there is also a considerable loss of CD34+ cells following most methods of T-cell depletion which could contribute to graft rejection or graft failure as well as delayed rates of hematopoietic Allogeneic PBSC grafts have contained 3 to 4 times more CD34' cells than BM, potentially allowing for T-cell depletion techniques to be performed with retention of relatively large numbers of CD34+
Initial in vitro studies showed that CD34' selection techniques could remove 2 to 3 logs of T cells from PBSC collections and preliminary clinical pilot studies have documented the feasibility of performing transplants with CD34' cell enriched PBSC.I3.l4 This pilot study was conducted to test whether rapid, sustained engraftment could be achieved with CD34+ selected G-CSF mobilized PBSCs from matched donors and whether CD34' selection had any apparent impact on the development of GVHD. An older population (age >35) was chosen for this study because this population is at greater risk for developing severe complications from GVHD and the risks of CD34' selection were better balanced by potential benefit. Patients and donors were asked to participate in a study evaluating transplants with PBSCs that had been enriched for CD34' cells as an alternative to BM or unmodified PBSCs. All patients and donors signed informed consent forms approved by the Institutional Review Board of the FHCRC or UCLA. The administration of G-CSF to normal donors was conducted under IND no. 523 1 issued by the US Food and Drug Administration.
Donors were family members who were HLA identical with the ~a t i e n t . '~ All donors received G-CSF (Amgen, Inc, Thousand Oaks, CA) 16 pgkg/d in 2 subcutaneous injections performed daily for 6 days. PBSCs were collected during a 12 L leukapheresis using a continuous flow blood cell separator (Cobe Laboratories, Lakewood, CO) at a flow rate of 50 to 70 " i n .
Collections were performed on days 4 to 7 with day 4 of G-CSF administration coinciding with recipient day 0.1.
PBSCs were processed daily using an avidin-biotin technique (Ceprate Columns; CellPro, Bothell, WA) with the infusion of each CD34' cell collection without cryopreservation on each of 4 consecutive days.' A 4 day separation was used to provide a large number of CD34' cells in the graft. Because approximately 50% of the CD34' cells are lost during the separation, 4 selection procedures were chosen to provide approximately the number of CD34' cells given in 2 days of PBSCs that are unmanipulated. The antibody used for CD34 selection is a mouse monoclonal IgM that has been previously described.'6 Day 0 was the first of 4 consecutive days of CD34+ PBSC infusions.
Eleven patients, 10 of whom were less than age 55, received 13.2 Gy and 5 patients older than age 55 received 12.0 Gy of total body irradiation (TBI) given in 1.2 Gy fractions t.i.d. followed by 120 mgkg of cyclophosphamide given in 2 daily doses of 60 mgkg. TBI was delivered by dual 60 cobalt sources at a dose rate of 5 to 8 cGy/min for 10 patients (FHCRC) and by a single linear accelerator at a dose rate of 5 to 7 cGy/min for 6 patients (UCLA).
Cyclosporine (CSA) was given to all patients for prophylaxis against GVHD. Cyclosporine 5 mgkg was administered as a continuous intravenous (IV) infusion over 24 hours from day -1 to +3, 3 mgkg from day +4 through day +14, and 3.75 mgkg from day +15 through day 35. Patients discharged from the hospital received 5 mgkg p.0. b.i.d. through day 83 with tapering doses to 2 mgkg by day 180. After the initial 5 patients were treated with CSA alone, methotrexate (MTX) was added to the prophylactic regimen for the remaining 11 patients; 15 mg/m2 was given IV on day +4 and 10 mg/m2 was given on days +6, +9, and + 14. Acute GVHD was treated initially with prednisone and failures were treated on protocols in effect at either institution." Chronic GVHD was treated with prednisone and CSA."
PBSCs were analyzed for CD34' cells and T-cell subsets by flow cytometry using previously published methods." Engraftment was documented by increasing neutrophil and platelet levels in the blood unsupported by transfusions, by in-situ Y chromosome hybridization of BM or blood samples in sex mismatched donor-recipient pairs and by analysis of variable number tandem repeat (VNTR) polymorphisms in BM and/or blood samples in the case of sex-matched pairs.20,21 Neutrophil engraftment was defined as the first of 2 consecutive days with an absolute neutrophil count (ANC) >500/pL following the posttransplant nadir. Platelet engraftment was defined as the first of 7 consecutive days with a platelet count >20,000/pL without platelet transfusions. Acute and chronic GVHD were graded as previously d e~c r i b e d .~~~~~
Patients who died posttransplant in relapse were categorized as dying of relapse irrespective of the proximate cause. Deaths of patients who had not relapsed were categorized as nonrelapse mortality. Infection was listed as the cause of death when bacterial, viral, and fungal infection was the approximate cause of death in the absence of relapse.
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RESULTS
Donors
. Donors tolerated the injections initially well but moderate bone pain that required acetaminophen with codeine occurred in 10 of 16 donors. Headache with nausea of moderate to severe intensity occurred in 1 donor and required acetaminophen with codeine. This donor also experienced transient elevations of liver function tests with peak SGPT of 257, SGOT 70, SGGT of 90 and alkaline phosphatase of 215. These returned to normal after 2 weeks. The other significant side effect was thrombocytopenia. Platelet counts below 100,00O/pL occurred in 8 of 12 donors after the first 3 collections. In 4 donors, by reinfusing platelets contained in the PBSC collection, none of the platelet counts dropped below 100,000.
The median number of CD34' cells collected was 18.64 X lO%g patient body weight and a median of 8.96 X lO%g patient body weight were recovered after processing on avidin-biotin columns ( Table 2 ). The median yield of CD34+ cells was 53% with a 62% median punty. The median number of CD3, CD4, and CD8 cells infused was 0.73, 0.40, and 0.32 X 106/kg, respectively, which represented a 2.78 (2.19 to 3.14) log depletion of T cells.
One patient died on day 3 of infection and was unevaluable for recovery of neutrophils ( Table 3) . ' The median day to achieve 500 neutrophils/pL was 15 (8 to 26) for the remaining 15 patients. Recovery to >500 neutrophils among those patients not given MTX occurred on day 13, whereas for those receiving MTX recovery occurred at a median of 19 days. Six of 16 patients failed to achieve a platelet count >20,00O/pL before death on days 3 to 97 of transplant related causes. The median day to achieve platelets >20,00O/mL in the remaining 10 patients was 11 (7 to 31). Platelets recovered earlier in those treated with CSA (day Results of CD34' selection.
Engrafhnent.
11) as compared to those treated with CSA and MTX (day 25).
Four patients had no significant infections during the transplant course. Two patients had clostridium difficile cultured in stool or heliobacter pylori from the stomach. Six patients had transient staphylococcus (n = 4) or enterococcus (n = 2) bacteremia. Four patients died of fatal infections with klebsiella, pseudomonas, aspergillis, and scedasporium prolifican on days 319, 97, 31, and 3, respectively. Two of these deaths were associated with grade 3 acute GVHD or progressive disease.
Three patients died early and were unevaluable and data were not obtained before death on day 97 of acute GVHD in 1 additional patient. Informative chimerism data were available from 12 patients. VNTR analysis of BM samples between days 21 to 100 posttransplant showed 99% to 100% donor cells in 6 out of 7 evaluable patients and 40% on day 30 in a patient who died on day 78 of progressive disease. In-situ Y chromosome studies of BM or peripheral blood showed 97% to 99.5% donor cells 30 to 90 days after transplant in 5 out of 5 evaluable patients.
Grade 2-4 acute GVHD occurred in 12 out of 14 (86%) and grades 3-4 in 6 out of 14 (43%) evaluable patients ( Table 3) . Three of the first 5 patients treated with CSA alone developed grade 3-4 acute GVHD as compared to 3 of 9 evaluable patients given CSA plus MTX. Four of 7 patients age 48 or under had grade 3-4 acute GVHD as compared to 2 out of 7 in patients over the age of 48. Specifics of organ system involvement with GVHD are presented in Table 4 . The median days to the development of skin, liver, and gastrointestinal tract involvement were 22, 22, and 25, respectively. Four of 6 evaluable patients developed clinical chronic GVHD and 2 patients developed subclinical chronic GVHD.
Infections.
Chimerism studies.
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DISCUSSION
Sixteen older patients with advanced hematologic malignancies received allogeneic CD34+ enriched PBSC after high-dose chemo-radiotherapy. All patients were at high-risk for failure of transplantation on the basis of advanced age and disease. PBSCs were procured from HLA-identical sibling donors following G-CSF administration and were then puri- 8,887 7  2  0  50  1  9,141  22  2  0  25  1  6,709  15  2  50  3  21  3  9,337  13  2  9  2  23  1  9,426  14  3  14  3  12  1  733  29  1  0  30  1  1,032  24  1  27  2  27  1  9,364  33  2  40  2  1  1,036  0  0  26  1  1,039  NE  NE  NE  9,380  8  3  12  2  6  2  1,046  25  2  0  0  9,240  12  2  0  13  1  10,050  10  3  43  4  43 For fied by positive selection for the CD34 antigen. Purification of early hematopoietic progenitors, with a resultant 2 to 3 log depletion of T cells, resulted in rapid and complete reconstitution of hematopoiesis without graft failure. The rate of hematopoietic recovery appeared to be somewhat faster than seen with marrow when patients receiving similar forms of GVHD prophylaxis are compared.
Despite the reduced number of residual T cells infused (0.43 to 3.65 X 106/kg), the incidence of grade 2-4 acute GVHD was high (12 out of 14 evaluable patients). In a series of 41 unselected PBSC allografts, Korbling et a1" infused a median of 393, 257, and 154 X lo6 CD3, CD4, and CD8 cells, respectively; approximately 3 log higher nembers of T cells than were given in the present study. Despite the 1,000-fold greater numbers of T cells acute GVHD was observed in only 48% of patients. These numbers compared with approximately 1 log fewer T cells given with unmanipulated marrow and no difference in the incidence of acute GVHD.
Grade 3-4 acute GVHD occurred in 3 out of 5 patients given CSA alone and GVHD prophylaxis was changed in subsequent patients to the addition of MTX. In the next cohort, 3 out of 9 patients given CSA plus MTX developed grades 3-4 acute GVHD suggesting that the added MTX may have decreased the incidence of severe acute GVHD.
It should be noted that because PBSC were given on 4 consecutive days the first dose of MTX was not given until day 4, 3 days after the first PBSCs were infused. This may have interfered with the effectiveness of MTX. The median number of T cells infused into recipients who developed grade 1-2 acute GVHD or grade 3-4 acute GVHD did not differ. In addition, 6 out of 8 evaluable patients developed clinical chronic GVHD.
Although the side effects of G-CSF administration to normal donors was tolerable, there was a high incidence of moderate to severe bone pain requiring codeine for relief.
In addition it was noted that significant thrombocytopenia occurred primarily from platelet losses in the collection product, because the re-infusion of platelets salvaged from the stem cell product prevented a further drop in platelet levels.
These data are consistent with those reported by Link et al'' where 3 out of S patients transplanted with CD34 selected allogeneic PBSC and CSA alone for prophylaxis of GVHD developed grade 3-4 acute GVHD, with 2 deaths from acute GVHD; all 3 surviving patients developed chronic GVHD. The median grade of acute GVHD for 5 similar patients given CSA plus MTX was 1 and 2 out of S developed chronic GVHD. In another study from our institution, using an immunomagnetic bead technique, all 6 patients transplanted with CD34 selected PBSC followed by CSA alone for GVHD prophylaxis developed grade 2 or 3 acute GVHD.Z4 These data contrast to those of Finke et al" where allogeneic transplantation with CD34 selected PBSCs, which were cryopreserved, resulted in grade 2 or 3 acute GVHD, limited to the skin, in only 2 out of 8 patients given CSA alone for GVHD prophylaxis. It is possible that cryopreservation modified the alloreactivity of the graft in this study."
Older patients were deliberately selected for this study because of the concern about a higher incidence and severity of GVHD in this patient population receiving unmodified BM transplants.*' If older patients get more acute GVHD than younger patients, this could partially explain the high incidence of acute GVHD seen in this study despite the removal of 2 to 3 logs of T cells. Because only limited numbers of patients over age SO have received allogeneic transplants, the exact increase in GVHD associated with advanced age is not known with certainty. In the current study, grade 3-4 acute GVHD was not more frequent in patients older than the median age of 48, suggesting that age was unlikely to be the entire explanation for the high incidence of GVHD. However, it is worth noting that the initial patient transplanted on this study (UPN 8887) is alive and well 580 days after transplant and may well be the oldest patient to receive an allogeneic transplant.
In a concurrent study of unmodified allogeneic PBSC in younger patients (median age of 38) the infusion of 3 logs more T cells than with BM transplantation was associated with a 37% and 14% incidence of grades 2-4 and 3-4 acute GVHD, respectively." This incidence of acute GVHD is no higher than would be anticipated following marrow transplantation showing that the infusion of large numbers of lymphocytes contained in G-CSF mobilized PBSC did not increase the incidence or severity of acute GVHD. Whether unmodified allogeneic PBSCs would have caused as high or a higher rate of acute GVHD than CD34' selected cells in patients with an age distribution of the present study is unknown.
The median dose of CD3 cells infused in this study was 0.73 x 106/kg, which is well above the 105/kg dose of T cells identified as the threshold for development of grade I -2 acute GVHD following marrow transplantation when no posttransplant immunosuppression was In previous studies T-cell doses up to 4.4 X 105/kg were not associated with any episodes of grade 3-4 acute GVHD.'* In another 
GVHD.
In conclusion, CD34 selected allogeneic PBSCs, in doses that are 3 times the usual BM CD34' cell dose, in older, high-risk patients with advanced hematologic malignancies provided rapid and sustained allogeneic reconstitution without graft-failure. However, CD34+ selection did not prevent acute and chronic GVHD from developing in most patients.
